{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sclc&page=4", "query": { "condition": "Sclc", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 4014, "total_pages": 402, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sclc&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sclc&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T23:33:12.236Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00958022", "title": "Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "LBH589 and carboplatin with etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ahmad Tarhini", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2009-09", "completion_date": "2011-06", "has_results": false, "last_update_posted_date": "2017-06-22", "last_synced_at": "2026-11-05T23:33:12.236Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00958022" }, { "nct_id": "NCT07412041", "title": "Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage II Lung Cancer", "Lung Cancer", "Non-small Cell Lung Cancer", "NSCLC" ], "interventions": [ { "name": "PERCC", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-01-22", "completion_date": "2028-03-30", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-11-05T23:33:12.236Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07412041" }, { "nct_id": "NCT04892472", "title": "EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "NovoTTF-200T", "type": "DEVICE" }, { "name": "Pembrolizumab (MK-3475) 200 mg", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "NovoCure GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 15, "start_date": "2021-07-12", "completion_date": "2025-01-10", "has_results": false, "last_update_posted_date": "2025-04-23", "last_synced_at": "2026-11-05T23:33:12.236Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04892472" }, { "nct_id": "NCT05736029", "title": "Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non Small Cell Lung Cancer", "Healthy" ], "interventions": [ { "name": "blood, stool and tissue samples collection", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "OncoHost Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "2022-11-07", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2023-02-21", "last_synced_at": "2026-11-05T23:33:12.236Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05736029" }, { "nct_id": "NCT03516981", "title": "A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Favezelimab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Quavonlimab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 245, "start_date": "2018-10-01", "completion_date": "2025-06-13", "has_results": true, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-11-05T23:33:12.236Z", "location_count": 19, "location_summary": "Tempe, Arizona • Sacramento, California • San Francisco, California + 15 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03516981" }, { "nct_id": "NCT02959437", "title": "Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors", "Advanced Malignancies", "Metastatic Cancer" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "INCB057643", "type": "DRUG" }, { "name": "INCB059872", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2017-02-27", "completion_date": "2020-03-02", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-11-05T23:33:12.236Z", "location_count": 8, "location_summary": "Duarte, California • La Jolla, California • Chicago, Illinois + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02959437" }, { "nct_id": "NCT00883675", "title": "Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Docetaxel-Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael Mann", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2009-05", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-11-05T23:33:12.236Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00883675" }, { "nct_id": "NCT00003281", "title": "Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "1998-04", "completion_date": "2006-03", "has_results": false, "last_update_posted_date": "2016-07-13", "last_synced_at": "2026-11-05T23:33:12.236Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003281" }, { "nct_id": "NCT00633529", "title": "Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "IMO-2055", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2007-11", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2013-10-22", "last_synced_at": "2026-11-05T23:33:12.236Z", "location_count": 9, "location_summary": "Ocoee, Florida • Indianapolis, Indiana • Albany, New York + 6 more", "locations": [ { "city": "Ocoee", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Albany", "state": "New York" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00633529" }, { "nct_id": "NCT04297605", "title": "Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Pemetrexed (Chemotherapy)", "type": "OTHER" }, { "name": "Nab-paclitaxel (Chemotherapy)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2020-05-15", "completion_date": "2028-01-30", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-11-05T23:33:12.236Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04297605" } ] }